Cost-effectiveness of left ventricular-assist devices in end-stage heart failure

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 2, 2008, Pages 175-185

  Hutchinson, Julia ^a   Scott, David A ^b   Clegg, Andrew J ^c   Loveman, Emma ^c   Royle, Pam ^d   Bryant, Jackie ^c   Colquitt, Jill L ^c  

^a Fourth Hurdle Consulting Ltd   (United Kingdom)

^b ICON PLC   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cost effectiveness; End stage heart failure; Heartmate ; Left ventricular assist device; Mechanical circulatory support; Novacor ; Quality adjusted life year

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANADA; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EVIDENCE BASED PRACTICE; HEART ASSIST DEVICE; HEART FAILURE; HUMAN; LONG TERM CARE; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; RELIABILITY; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; UNITED KINGDOM; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEART VENTRICLE;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS;

EID: 40149097340     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.2.175     Document Type: Review

References (44)

1. Clegg AJ, Scott DA, Loveman E et al. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation. Health Technol. Assess. 9, 1-148 (2005).
2. Dunlap SH, Mallemala S, Sueta CA, Schwartz TA, Adams Jr KF. Survival rates are similar between African American and white patients with heart failure. Am. Heart J. 146, 265-272 (2003).
3. Co peland JG, Smith RG, Arabia FA et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N. Engl. J. Med. 351, 59-67 (2004).
4. Petersen S, Rayner M, Wolstenholme J. Coronary Heart Disease Statistics: Heart Failure Supplement. British Heart Foundation, Oxford, UK (2002).
5. Deng MC. Orthotopic heart transplantation: highlights and limitations. Surgical Clinics of North America 84, 243-255 (2004).
6. Wyngaarden JB, Smith LH, Bennett JC. Cecil Textbook of Medicine. WB Saunders, London, UK (1992).
7. Cleland JGF. Heart failure: a medical hydra. Lancet 352, 15-18 (1998).
8. Department of Health. Chapter 6: Heart Failure. In: National Service Framework for Coronary Heart Disease: Modern Standards and Service Models. Department of Health, London, UK (2003).
9. Department of Health and Human Services. Annual report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients Department of Health and Human Services, Washington DC, USA (2001).
10. Souhami RL, Moxham J. Textbook of Medicine. Churchill Livingstone, London, UK (1994).
11. Mahmood AK, Courtney JM, Akdis M, Reul H, Westaby S. Critical review of current left ventricular assist devices. Perfusion 15, 399-420 (2000).
12. Park SJ, Tector A, Piccione W et al. Left ventricular assist devices as destination therapy: a new look at survival. J. Thorac. Cardiovasc. Surg. 129, 9-17 (2005).
13. Rose EA, Moskowitz AJ, Packer M et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann. Thorac. Surg. 67, 723-730 (1999).
14. Morales DL, Catanese KA, Helman DN et al. Six-year experience of caring for forty-four patients with a left ventricular assist device at home: safe, economical, necessary. J. Thorac. Cardiovasc. Surg. 119, 251-259 (2000).
15. Cloy MJ, Myers TJ, Stutts LA et al. Hospital charges for conventional therapy versus left ventricular assist system therapy in heart transplant patients. ASAIO J. 41, M535-M539 (1995).
16. Christopher F, Clegg AJ. Left ventricular assist devices (LVADs) for end stage heart failure. Development and Evaluation Committee Report 103. Wessex Institute for Health Research and Development, Southampton, UK (1999).
17. Frazier OH, Rose EA, McCarthy P et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann. Surg. 222, 327-336 (1995).
18. Moskowitz AJ, Weinberg AD, Oz MC et al. Quality of life with an implanted left ventricular assist device. Ann. Thorac. Surg. 64, 1764-1769 (1997).
19. Skinner JL, Harris C, Aaron MF et al. Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices. ASAIO J. 46, 587-589 (2000).
20. Mir SH, Kshettry VR, Kubo SH et al. Effects of the HeartMate left ventricular assist device on clinical outcomes and cost in status I heart trasplantation patients. Circulation 96, 2055 (1997).
21. Perry M, Ormanza SMI. Daily costs reduced for status 1 heart transplant (HT) patients following bridge with Heartmate left ventricular assist device (LVAD). J. Heart Lung Transplant. 16, 57 (1997).
22. Kolbye A, Sander Jensen KM, Aldershvile J et al. Economic aspects of implementation of the mechanical heart, "HeartMate". Ugeskr Laeger 162, 3722-3725 (2000).
23. Arabia FA, Smith RG, Jaffe C et al. Cost analysis of the Novacor left ventricular assist system as an outpatient bridge to heart transplantation. ASAIO J. 42, M546-M549 (1996).
24. Schiller W, Reichart B. Cost analysis of treatment with the portable Novacor-left-heart-assist system. In: Economics of surgical procedures. Szucs T, Haverisch A, Oder J (Eds). JA Barth, Heidelberg, Germany, 33-38 (2000).
25. Conseil D'evaluation des Technologies de la Sante du Quebec. Implantable ventricular assist devices: should they be used in Quebec? Conseil d'Evaluation des Technologies de la Sante (CETS), Quebec, Canada (2000).
26. Mehra SM, Aufiero TX, Pae W-EJ et al. Mechanical ventricular assistance: an economical and effective means of treating end-stage heart disease. Ann. Thorac. Surg. 60, 284-290 (1995).
27. Couper GS, Dekkers RJ, Adams DH et al. The logistics and cost-effectiveness of circulatory support: advantages of the ABIOMED BVS 5000. Ann. Thorac. Surg. 68, 646-649 (1999).
28. Christensen DM, Frazier PA, Messner R et al. Save me the money: a cost comparison of inpatient vs outpatient care of left ventricular assist device patients. J. Am. Coll. Cardiol. 33(2), 204A (1999).
29. Gelijns AC, Richards AF, Williams DL et al. Evolving costs of long-term left ventficular assist device implantation. Ann. Thorac. Surg. 64, 1312-1319 (1997).
30. Moskowitz AJ, Williams DL, Tierney A et al. Economic considerations of left ventricular assist device implantation. In: Cardiac Assist Devices. Goldstein DJ, Oz MC (Eds), Futura Publishing, NY, USA, 183-191 (2000).
31. Miller LW, Mogovern G, Shannon RP et al. Costs of LVAD implantation: Lessons from the REMATCH trial. Presented at The American Heart Association Scientific Sessions, November 17-20 (2002).
32. Schulze B, Tenderich G, Hansky B et al. In hospital costs of left ventricular assist device (Novacor) in comparison to different therapeutic strategies in end stage heart disease. Int. J. Artificial Organs 23(8), 553 (2000).
33. Oz MC, Grewal R, Gelijns A. Cost considerations for long-term mechanical circulatory support. ASAIO J. 43, 268-270 (1997).
34. Miners AH, Garau M, Fidan D et al. Comparing estimates of cost-effectiveness submitted to the National Institute for Clinical Excellence. BMJ 330, 65-68 (2005).
35. Stevenson LW, Miller LW, Desvigne-Nickens P et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 110, 975-981 (2004).
36. Long JW, Kfoury AG, Slaughter MS et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest. Heart Fail. 11, 133-138 (2005).
37. DiGiorgi PL, Reel MS, Thornton B, Burton E. Naka Y, Oz MC. Heart transplant and left ventricular assist device costs. J. Heart Lung Transplant. 24, 200-204 (2005).
38. Miller LW, Nelson KE, Bostic RR, Tong Y, Slaughterhouse MS, Long JW. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era. J. Heart Lung Transplant. 25, 778-784 (2006).
39. Sharples LD, Dyer M, Cafferty F et al. Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK). J. Heart Lung Transplant. 25, 1336-1343 (2006).
40. Clegg AJ, Scott DA, Loveman E, Colquitt J, Royle P, Bryant J. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: a systematic review and economic evaluation. Int. J. Technol. Assess. Health Care 23, 261-268 (2007).
41. Clegg AJ, Scott DA, Loveman E, Colquitt J, Royle P, Bryant J. Clinical and cost-effectiveness of left ventricular assist devices as a bridge to heart transplantation for people with end-stage heart failure: a systematic review and economic evaluation. Eur. Heart J. 27, 2929-2938 (2006).
42. Chen E, Sapirstein W, Ahn C, Swain J, Zuckerman B. FDA perspective on clinical trial design for cardiovascular devices. Ann. Thorac. Surg. 82, 773-775 (2006).
43. Grunkemeier GL, Jin R, Starr A. Prosthetic heart valves: objective performance criteria versus randomized clinical trial. Ann. Thorac. Surg. 82, 776-780 (2006).
44. Esmore DS, Kaye D, Negri JC et al. Cumulative support outcomes of 3 clinical trials for the VentraAssist LVAD. Presented at The International Society for Heart & Lung Transplantation (ISHLT) 27th Annual Meeting, San Francisco, USA, April 25-28, 2007.